Gold soars to record high over $3,900/oz amid yen slump, US rate cut bets
Investing.com - H.C. Wainwright raised its price target on Maze Therapeutics (NASDAQ:MAZE) to $50.00 from $34.00 on Monday, while maintaining a Buy rating on the stock. The company’s shares have shown remarkable momentum, surging over 55% in the past week. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $27 to $50.
The price target increase follows Phase 1 healthy volunteer data from Maze’s MZE782 program, a SLC6A19 small molecule inhibitor, which demonstrated a robust pharmacodynamic signal that exceeded the benchmark set by JNT-517 in healthy volunteers.
H.C. Wainwright noted that the data reinforces the potential for MZE782 to be best-in-class for treating phenylketonuria (PKU), a rare genetic disorder that affects the body’s ability to process the amino acid phenylalanine.
An unexpected finding from an exploratory analysis revealed a dose-dependent, reversible estimated glomerular filtration rate (eGFR) dip, suggesting MZE782 might have therapeutic applications in chronic kidney disease (CKD) similar to SGLT2 inhibitors.
The research firm indicated that the eGFR dip pattern appears consistent with benign hemodynamic mechanisms seen in ACEi/ARB/SGLT2i treatments, but emphasized that Phase 2 trials must confirm this finding with injury biomarkers and demonstrate a link to proteinuria/UACR reduction.
In other recent news, Maze Therapeutics has been the focus of significant analyst attention following promising Phase 1 data for its lead drug candidate, MZE782. H.C. Wainwright raised its price target on Maze Therapeutics to $50.00 from $34.00, maintaining a Buy rating, due to robust pharmacodynamic signals that surpassed competitors’ benchmarks. Similarly, BTIG increased its price target to $37.00 from $30.00, also maintaining a Buy rating, after the drug showed substantial increases in urinary phenylalanine excretion, exceeding management’s previous guidance. Additionally, BTIG initiated coverage on Maze with a Buy rating and a $30.00 price target, citing the company’s potential leadership in APOL1-mediated kidney disease with its MZE829 drug candidate.
Maze Therapeutics also announced the appointment of Misbah Tahir as chief financial officer and principal financial officer, effective immediately. Before joining Maze, Tahir held the CFO position at IGM Biosciences and various finance leadership roles at other notable companies. Furthermore, H.C. Wainwright has initiated coverage on Maze with a Buy rating and a $34.00 price target, highlighting the potential of the company’s kidney disease treatment as a "game changer." These developments underscore the growing interest and optimism surrounding Maze Therapeutics’ drug pipeline and executive leadership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.